Protein kinase inhibitors for amyotrophic lateral sclerosis therapy
Valle Palomo(Biomedical Research Networking Center on Neurodegenerative Diseases), Ana Martı́nez(Consejo Superior de Investigaciones Científicas), Vanesa Nozal(Centro de Investigaciones Biológicas Margarita Salas), Carmen Gil(Instituto de Salud Carlos III)
Cited by 47
Related Papers
COVID-19: Drug Targets and Potential Treatments
|Journal of Medicinal Chemistry|2020|469
First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease
|Journal of Medicinal Chemistry|2002|448
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
|Frontiers in Molecular Neuroscience|2011|348
Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation
|Medicinal Research Reviews|2002|334
TNFα disrupts blood brain barrier integrity to maintain prolonged depressive-like behavior in mice
|Brain Behavior and Immunity|2018|293